Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 08, 2022

SELL
$1.74 - $2.4 $232,638 - $320,880
-133,700 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$9.26 - $14.36 $42,596 - $66,056
4,600 Added 3.56%
133,700 $1.32 Million
Q4 2020

Feb 05, 2021

SELL
$9.84 - $14.26 $104,304 - $151,156
-10,600 Reduced 7.59%
129,100 $1.4 Million
Q3 2020

Nov 09, 2020

BUY
$10.3 - $21.64 $58,710 - $123,348
5,700 Added 4.25%
139,700 $1.44 Million
Q2 2020

Aug 05, 2020

BUY
$8.53 - $25.64 $162,070 - $487,160
19,000 Added 16.52%
134,000 $2.8 Million
Q1 2020

May 08, 2020

BUY
$7.98 - $16.32 $81,396 - $166,464
10,200 Added 9.73%
115,000 $1.12 Million
Q4 2019

Feb 06, 2020

BUY
$5.12 - $12.22 $536,576 - $1.28 Million
104,800 New
104,800 $1.21 Million

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.